CLOs on the Move

VeriTeQ Corp

www.veriteqcorp.com

 
VeriTeQ's core technology evolved from implantable radio frequency identification (RFID) microchip technology used in the health care community for over two decades. This first-of-its-kind implantable RFID technology was cleared for use by the FDA in 2004 as a Class II medical device, originally to identify at-risk patients at the point of care. It has now evolved to help medical device manufacturers meet mandatory regulations outlined in the FDA's Safety & Innovation Act, signed into law in July 2012, and the FDA's Unique Device Identification (UDI) Final Rule. This technology is VeriTeQ's Q Inside Safety Technology. VeriTeQ's dosimeter technologies are used in the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.veriteqcorp.com
  • 220 Congress Park Drive Suite 200
    Delray Beach, FL USA 33445
  • Phone: 561.846.7000

Executives

Name Title Contact Details
Michael Krawitz
Chief Legal Officer Profile

Similar Companies

Flosonics

Flosonics Medical is a venture-backed start-up that develops and commercializes wearable sensors, which improve clinical management of critically ill patients inside and outside of the hospital.

Meinhard Glass Products

Meinhard Glass Products is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Visage imaging

Visage imaging is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Innercool Therapies

Innercool Therapies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.